Kala Pharmaceuticals Stock Investor Sentiment

KALA Stock  USD 7.03  0.18  2.50%   
About 62% of Kala Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Kala Pharmaceuticals stock suggests that many investors are alarmed at this time. The current market sentiment, together with Kala Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kala Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
over a week ago at www.macroaxis.com         
Acquisition by Todd Bazemore of 45200 shares of Kala Pharmaceuticals at 7.05 subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 2093 shares by Todd Bazemore of Kala Pharmaceuticals at 6.09 subject to Rule 16b-3
Macroaxis News
over two weeks ago at gurufocus.com         
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference
Gurufocus Stories at Macroaxis
over three weeks ago at www.macroaxis.com         
Acquisition by Reumuth Mary of 10100 shares of Kala Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over a month ago at gurufocus.com         
Cormorant Asset Management, LP Acquires Significant Stake in Kala Bio Inc
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
KALA BIO Announces CEO Resignation and Appointment of Interim Chief Executive OfficerOn February 11,...
news
over a month ago at thelincolnianonline.com         
KALA BIOs Buy Rating Reaffirmed at HC Wainwright
news
over a month ago at gurufocus.com         
KALA BIO Announces Chief Executive Officer Transition
Gurufocus Stories at Macroaxis
over a month ago at thelincolnianonline.com         
KALA BIO, Inc. Short Interest Update
news
over a month ago at news.google.com         
KALA stock soars to 52-week high, reaching 8.81 By Investing.com - Investing.com Nigeria
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 7392 shares by Mark Iwicki of Kala Pharmaceuticals at 6.09 subject to Rule 16b-3
Macroaxis News
over two months ago at thelincolnianonline.com         
KALA BIO, Inc. CEO Sells 44,093.77 in Stock
news
over two months ago at thelincolnianonline.com         
Insider Selling KALA BIO, Inc. Insider Sells 2,021 Shares of Stock
news
over two months ago at thelincolnianonline.com         
KALA BIO, Inc. CFO Mary Reumuth Sells 1,706 Shares
news
over two months ago at news.google.com         
Kala Bios head of research sells 18,662 in stock By Investing.com - Investing.com Australia
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Kala Pharmaceuticals that are available to investors today. That information is available publicly through Kala media outlets and privately through word of mouth or via Kala internal channels. However, regardless of the origin, that massive amount of Kala data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kala Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kala Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kala Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kala Pharmaceuticals alpha.

Kala Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Kala Stock analysis

When running Kala Pharmaceuticals' price analysis, check to measure Kala Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kala Pharmaceuticals is operating at the current time. Most of Kala Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kala Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kala Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kala Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges